Enhanced expression of complement and microglial-specific genes prior to clinical progression in the MOG-experimental autoimmune encephalomyelitis model of multiple sclerosis

Brain Res Bull. 2020 Dec:165:63-69. doi: 10.1016/j.brainresbull.2020.09.010. Epub 2020 Sep 23.

Abstract

Understanding the biological changes responsible for failures in repair and the development of progressive MS is paramount for therapeutic intervention. In a well characterized experimental autoimmune encephalomyelitis (EAE) model of MS the clinical phenotype features an acute attack with partial recovery followed by a chronic or progressive disease phase. Neuropathology-focused gene expression profiles were generated from spinal cord, hindbrain and forebrain of mice 25 days after the induction of EAE, the time when recovery plateaus and transitions to a chronic or worsening phase. Differences in gene expression were most pronounced in the spinal cord of EAE mice compared to sham-immunized animals, with a subset of genes also found to be differentially expressed in the hindbrain and the forebrain, albeit with smaller fold-changes in expression. Our data suggests that changes in complement components, chemoattractant cytokines and especially enrichment in microglial cells may be the primary drivers of processes that limit recovery in EAE.

Keywords: Complement; Experimental autoimmune encephalomyelitis; Gene expression; Microglia; Multiple sclerosis; Progressive MS.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Complement System Proteins / genetics*
  • Complement System Proteins / metabolism
  • Disease Progression
  • Encephalomyelitis, Autoimmune, Experimental / genetics*
  • Encephalomyelitis, Autoimmune, Experimental / metabolism
  • Female
  • Gene Expression Profiling
  • Mice
  • Microglia / metabolism*
  • Myelin-Oligodendrocyte Glycoprotein
  • Prosencephalon / metabolism*
  • Spinal Cord / metabolism*

Substances

  • Myelin-Oligodendrocyte Glycoprotein
  • Complement System Proteins